The Indian Practitioner

The PDF file you selected should load here if your Web browser has a PDF reader plug-in installed (for example, a recent version of Adobe Acrobat Reader).

If you would like more information about how to print, save, and work with PDFs, Highwire Press provides a helpful Frequently Asked Questions about PDFs.

Alternatively, you can download the PDF file directly to your computer, from where it can be opened using a PDF reader. To download the PDF, click the Download link above.

Fullscreen Fullscreen Off

   Subscribe/Renew Journal


Biomarkers have reformed the game of diagnosis and prognosis of diseased conditions over the last 50 years. They have become powerful tools to classify patients according to their risk of disease progression, severity of the disease and guide drug therapy. The Food and Drug Administration (FDA) currently listed over 39 biomarkers that may be used as outcomes for FDAapproved therapeutics. Moreover, in association with NIH, FDA has published the B.E.S.T. resource to establish uniformity and harmonization categorically for the discussion of biomarkers. This article briefly touches upon this harmonization and uniformity brought in by FDA and NIH in terms of discussions related to biomarkers for the ease of everyone’s understanding and information, its Biomarker Qualifying Programme, what are the Top 10 diseases causing deaths worldwide according to WHO and which biomarkers are used for their diagnosis and prognosis. Briefly, this article captures how far we have progressed in these 50 years and how elusive and distant the dream of gold standard biomarkers still is.


Keywords

Biomarkers, FDA, NIH, FDA-NIH Biomarker Working Group, B.E.S.T resource, WHO
Subscription Login to verify subscription
User
Notifications
Font Size